ReviewNeuro-degenerative diseases2026
Spinocerebellar Ataxia Type 12: Spectrums of Movement Disorders and Clinical Features.
Review in Neuro-degenerative diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpinocerebellar ataxia type 12 (SCA12) is a neurodegenerative disorder caused by a CAG repeat expansion in the PPP2R2B gene. It is characterized by tremor, cerebellar ataxia, and a wide range of neurological symptoms. The heterogeneity of SCA12 symptoms, particularly in movement presentation, highlights the need for standardized studies to better define its clinical spectrum. SUMMARY: This review evaluates the spectrum of movement disorder symptoms, focusing on their type, age of onset, and progression, and highlights areas requiring further research. Tremor, typically action or postural, is often the initial symptom, followed by progressive cerebellar dysfunction, including gait instability, dysmetria, and dysdiadochokinesia, supported by neuroimaging evidence of cerebellar atrophy. Other movement-related features, such as dystonia and parkinsonism, further complicate the clinical picture. Psychiatric manifestations, including cognitive decline and depression, are also reported, though their prevalence varies. A clear characterization of the movement symptoms of SCA12 will guide future research into targeted therapeutic strategies, addressing the significant unmet needs of affected patients. This review underscores the importance of a multidisciplinary approach to studying SCA12, combining all relevant clinical data to advance knowledge and improve patient outcomes. KEY MESSAGES: SCA12 presents predominantly with tremor, often preceding cerebellar signs by years. The clinical phenotype is broader than previously recognized, including dystonia, parkinsonism, and neuropsychiatric symptoms. Clinical variability may delay suspicion of SCA12, supporting early genetic testing. Systematic clinical characterization is critical for improving patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.